The expression and clinical significance of HERC4 in breast cancer

Cancer Cell International

Wen-Li Ma¹  Jue-Yu Zhou¹  Wen-Ling Zheng¹  Min Wei¹  Rong Shi¹  Hui Zhou¹ 

[1] Institute of Genetic Engineering, Southern Medical University, Guangzhou 510515, China

关键词: Clinical stage;    Histopathological grade;    Tissue microarray;    Breast cancer;    HERC4;   

Others  :  792628
DOI  :  10.1186/1475-2867-13-113

 received in 2013-10-11, accepted in 2013-11-04,  发布年份 2013

【 摘 要 】

Background

Increasing evidence suggest that ubiquitin-proteasome system (UPS) plays a key role in tumorigenesis. HERC4 is a recently identified ubiqutin ligase. However, the expression status and biological functions of HERC4 in cancers are not clearly.

Methods

We evaluated the HERC4 expression in breast cancer cell lines and breast tumor tissues by quantitative real-time PCR and western blot analysis. To investigate the clinicopathological significance of HERC4, immunohistochemistry analysis for HERC4 was performed on a tissue microarray including 13 benign fibroadenoma, 15 intraductal carcinoma, 120 histologically confirmed invasive ductal carcinoma. Receiver operating characteristic (ROC) analysis was applied to determine the optimal cut-off score for positive expression of HERC4, when HERC4 positive expression percentage was above 60%, tumor was defined as “positive”.

Results

HERC4 was up-regulated in breast cancer cell lines and breast tumor tissues compared to non-tumorigenic cell line and adjacent normal breast tissues. According to ROC analysis, HERC4 positive expression was detected in 1/16 (6.3%) of normal breast tissue, in 3/13 (23.1%) of fibroadenoma, in 6/15 (40%) of intraductal carcinoma and 66/120 (55%) of invasive ductal carcinoma. Positive expression of HERC4 was positively correlated with pT status, pN status, clinical stage and histological grade of patients with invasive ductal carcinoma (p < 0.05).

Conclusions

Our findings suggest that HERC4 was a significant diagnostic marker for invasive ductal carcinoma of the breast.

【 授权许可】

   
2013 Zhou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS: The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastas 2012, 29(7):807-819.
• [2]Chavez-MacGregor M, Gonzalez-Angulo AM: Breast cancer in 2012: New drugs, new knowledge, new targets. Nat Rev Clin Oncol 2013, 10(2):75-76.
• [3]Habbu R, Adams JE: Role of elective hand surgery and tourniquet use in patients with prior breast cancer treatment. J Hand Surg 2011, 36(9):1537-1539. quiz 1540
• [4]Haloua MH, Krekel NM, Winters HA, Rietveld DH, Meijer S, Bloemers FW, van den Tol MP: A systematic review of oncoplastic breast-conserving surgery: current weaknesses and future prospects. Ann Surg 2013, 257(4):609-620.
• [5]Christinat A, Pagani O: Fertility after breast cancer. Maturitas 2012, 73(3):191-196.
• [6]Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F: Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-related Cancer 2005, 12(4):721-747.
• [7]Patani N, Martin LA, Dowsett M: Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 2013, 133(1):1-13.
• [8]Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M: Current and future anti-HER2 therapy in breast cancer. J BUON 2013, 18(1):4-16.
• [9]Morrow PK, Zambrana F, Esteva FJ: Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res 2009, 11(4):207. BioMed Central Full Text
• [10]Wang S, Huang X, Li Y, Lao H, Zhang Y, Dong H, Xu W, Li JL, Li M: RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology 2011, 53(6):1932-1942.
• [11]Orlowski RZ, Dees EC: The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 2002, 5(1):1-7. BioMed Central Full Text
• [12]Yang WL, Zhang X, Lin HK: Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene 2010, 29(32):4493-4503.
• [13]Li W, Ye Y: Polyubiquitin chains: functions, structures, and mechanisms. Cell Mol Life Sci 2008, 65(15):2397-2406.
• [14]Yamasaki L, Pagano M: Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 2004, 16(6):623-628.
• [15]Deng CX, Scott F: Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 2000, 19:1059-1064.
• [16]Ji Y, Walkowicz MJ, Buiting K, Johnson DK, Tarvin RE, Rinchik EM, Horsthemke B, Stubbs L, Nicholls RD: The ancestral gene for transcribed, low-copy repeats in the Prader-Willi/Angelman region encodes a large protein implicated in protein trafficking, which is deficient in mice with neuromuscular and spermiogenic abnormalities. Hum Mol Genet 1999, 8(3):533-542.
• [17]Nishimoto T: A new role of ran GTPase. Biochem Bioph Res Co 1999, 262(3):571-574.
• [18]Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75(3):495-505.
• [19]Hochrainer K, Mayer H, Baranyi U, Binder B, Lipp J, Kroismayr R: The human HERC family of ubiquitin ligases: novel members, genomic organization, expression profiling, and evolutionary aspects. Genomics 2005, 85(2):153-164.
• [20]Hochrainer K, Kroismayr R, Baranyi U, Binder BR, Lipp J: Highly homologous HERC proteins localize to endosomes and exhibit specific interactions with hPLIC and Nm23B. Cell Mol Life Sci 2008, 65(13):2105-2117.
• [21]Rodriguez CI, Stewart CL: Disruption of the ubiquitin ligase HERC4 causes defects in spermatozoon maturation and impaired fertility. Dev Biol 2007, 312(2):501-508.
• [22]Coradini D, Daidone MG: Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol 2004, 16(1):49-55.
• [23]Jensen JD, Knoop A, Ewertz M, Laenkholm AV: ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 2012, 132(2):511-521.